Our preclinical observations are confirmed in a patient data set with urothelial cancers, where the expression of IRAK3 mRNA in pretreatment tumor tissues is associated with the inflammatory signatures and the treatment outcome of ICB therapy. The gene discussed is IRAK3; the disease is neoplasm.